Larimar Therapeutics to Initiate Rolling BLA Submission for Nomlabofusp in June 2026

summarizeSummary

Larimar Therapeutics announced plans to begin a rolling BLA submission for nomlabofusp in June 2026 and expects topline open-label study data in Q2 2026, alongside a strong cash position extending into Q2 2027.

check_boxKey Events

• Rolling BLA Submission Initiated

  Larimar Therapeutics plans to begin a rolling Biologics License Application (BLA) submission for nomlabofusp in June 2026, seeking accelerated approval for Friedreich's ataxia, with final modules expected in the second half of 2026.

• Topline Open-Label Study Data Expected

  Topline data from the open-label study, intended to support the BLA submission, is anticipated in the second quarter of 2026.

• Strong Cash Position and Runway

  The company reported $200.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a projected cash runway into the second quarter of 2027.

• Global Phase 3 Study Planned

  Dosing of the first patient in the global confirmatory Phase 3 study for nomlabofusp is expected to initiate in mid-2026.

auto_awesomeAnalysis

This 8-K provides a critical update on the regulatory path for nomlabofusp, Larimar's lead candidate for Friedreich's ataxia. The company plans to initiate a rolling Biologics License Application (BLA) submission for accelerated approval in June 2026, starting with nonclinical and clinical modules. This sets a clear near-term timeline for a major regulatory milestone. Additionally, topline data from the open-label study, which will support the BLA, is expected in Q2 2026, providing another significant catalyst. The company also reported a strong cash position of $200.4 million, extending its runway into Q2 2027, which is crucial for funding ongoing development and the planned global Phase 3 study.